ASCO 2020: Lymphoma
Filter Results
Safety & Short-Term Efficacy of ALLO-501 for Lymphoma
ALLO-501, an anti-CD19 allogeneic CAR T-cell therapy, shows promise among relapsed/refractory non-Hodgkin lymphoma patients, according to initial findings presented at the ASCO 2020 Annual Meeting (Abstract 8002).
Promising Responses of Allogeneic Stem Cell Transplantation for DLBCL
A significant portion of patients with diffuse large B-cell lymphoma (DLBCL) had durable responses after allogeneic stem cell transplant (alloHCT), despite high rates of graft-versus-host disease (GVHD) and wide-ranging disease status, according to work presented at the 2020 ASCO Annual Meeting.
Pembrolizumab Shows Significantly Improved PFS in R/R Classic Hodgkin Lymphoma
A new study presented at the 2020 ASCO Annual Meeting showed that pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with brentuximab vedotin (BV) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL) (Abstract 8005).
New Treatment Approach in Pediatric Classical Hodgkin Lymphoma
A new treatment approach tailored to risk for relapse and response to induction therapy is associated with high response rates in children and young adults with very high-risk classic Hodgkin lymphoma, according to the most recent results from the Checkmate 744 study presented at the 2020 ASCO Annual Meeting (Abstract 8013). To explore additional resources offered by Oncology Times and to subscribe, visit https://journals.lww.com/oncology-times/pages/default.aspx
Durable Remission, Rare Adverse Effects With Anti-CD19 CAR-T Therapy
Anti-CD19 CAR T-cell therapy is associated with highly durable remissions in relapsed B-cell lymphoma and chronic lymphocytic leukemia (CLL), according to research presented at the 2020 ASCO Annual Meeting (Abstract 3012).
Mostly Low-Grade, Late-Onset Toxicity With Liso-Cel in R/R Large B-Cell Lymphoma
Patients with high-risk, relapsed or refractory large B-cell lymphoma showed a low incidence of cytokine release syndrome (CRS) or neurologic events when treated with lisocabtagene maraleucel (liso-cel), according to results from the TRANSCEND NHL 001 trial presented at the 2020 ASCO Annual Meeting (Abstract e20046).